Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus IRBESARTAN HYDROCHLOROTHIAZIDE.
AVALIDE vs IRBESARTAN HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Oral, 150 mg irbesartan/12.5 mg hydrochlorothiazide once daily, titrated to 300 mg irbesartan/25 mg hydrochlorothiazide once daily based on BP response.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Irbesartan: 11–15 hours terminal half-life; supports once-daily dosing with steady state by 3 days. Hydrochlorothiazide: 6–15 hours terminal half-life; prolonged in renal impairment (up to 20+ hours) requiring dose adjustment.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Irbesartan: primarily fecal (80%) via biliary excretion, with ~20% renal. Hydrochlorothiazide: primarily renal (≥95% as unchanged drug) via tubular secretion.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB